Category Archives: Cancer

Home / Cancer
4 Posts

Oncotarget is a worldwide, peer-investigated diary concentrating on the neurotic premise of all growths. It focuses on treatment conventions utilized to enhance the administration of tumor patients. It is mainly focused on the oncology and cancer-related diseases.The diary additionally concentrates on the effect of administration programs and new remedial operators and conventions on tolerant points of view, for example, personal satisfaction, adherence, and fulfillment.This diary investigates the proof behind new and existing treatments as far as enhancing results and, significantly, will try to characterize their utilization as far as extreme take-up and acknowledgment by the patient and social insurance proficient.In participation with the National Library of Medicine, Oncotarget is accomplishing its objective to wind up noticeably the principal look into the dairy to present a whole issue to PubMed days after online distribution.

It works intimately with all prominent logical records and files to make logical outcomes quickly and broadly accessible to medicinal field scientists, experts, and the overall population. It has an end goal to quicken ordering forms. It is distributing two issues every week.Oncotarget believe that it is important to address the difficulties of the 21st century, which are the reason its main goal continues to be an academic diary surely understood for fast and wide-scale dispersal of regarded bio-medicinal research. It has also made several contributions in the said Legal Affairs and the external offices of Oncotarget.Finally, Oncotarget will remain focused to help all analysts with their commitment to the advance and upgrade in science as they endeavor to see good existence without ailment.

Who is Oncotarget?

Oncotarget is a multidisciplinary customary diary with free-get to. Oncotarget distributes papers online with a mission to make logical outcomes quickly and broadly accessible, to expand the effect of research through a keen audit, and to dispense with the fringe between biomedical claims to fame.Oncotarget encourages utilization of essential and clinical science to battle sickness. Under the authority of the most conspicuous researchers, the diary encourages all analysts to add to the advance of science. Oncotarget endeavors to see an existence without illness.

Oncotarget is a weekly global medical journal that is peer-reviewed and focuses on the pathological basis of cancers and the treatment protocols employed in improving and managing the cancer patients. Oncotarget also put its focus on the management program impacts by exploring evidence on the new and existing therapies with the aim of improving the lives of the cancer patients. Being published in English, it allows the majority people around the globe to read it due to broad acceptance of the English language around the world.Through the publication of the journal by Mikhail Blasgosklonny, Oncotarget has gained an excellent reputation with an incredible impact.

Increased Publication

Due to the improvement in volume, quality, and impact, Oncotarget is now publishing two issues every week – on Tuesday and Friday. It has enabled the journal to relay highly crucial scientific information making it a leading journal. Oncotarget has also increased in popularity due to punctual, insightful, constructive, and multiple peer-review.It aims at making the scientific results widely and rapidly available to the readers with the help, guidance, and input of the most prominent scientist. The journal has helped researchers to contribute the progress of the science and its ultimate goal is to ensure life is without the diseases.

Why Oncotarget is the Best Journal

The journal has primarily provided the scientific research by eliminating the boundaries between different medical fields. The success of Oncotarget is also evident where it encourages and allows the editors to add more sections including Molecular Biology, Aging, Cardiology, Metabolism, Endocrinology, among many others.The Oncotarget website is freely accessible and people are free to use the information in conducting their research. An individual can extract particular details with the use of a unique search feature. It is quick, reliable, and informative.It has also perfected the art of using social media. Oncotarget has various social media accounts such as Facebook, and it remains the best journal to learn about scientific information.

In Fortune’s article “This Is What’s Missing in the Data Centric Approach to Cancer”, Barb Darrow discusses Erik Lefkofsky’s new venture.

Erik Lefkofsky is the co-founder and CEO Tempus. The startup was created to develop cancer databases to change cancer treatment into a combination of clinical data and molecular data.

He attended Fortune’s Brainstorm Health conference in San Diego where he discussed what’s missing from the current medical research system. Part of the problem today is that the researchers don’t have easy access to the data. For example, Lefkofsky states that “if you were to go into any of the cancer centers and ask who took Herceptin over two years and how they did, they’d need a grant and at least 90 days.”

Lefkosky started Tempus as a way to ameliorate the situation. Not only does it add technology to the existing electronic medical record, but it gathers the information and provides a unique approach to treatment. By creating a large aggregate data pool, the data for each individual can be used to discover patterns similarities between the results and the treatment.

The realization that drastic systematic change to cancer treatment was vital occurred after his wife was diagnosed with cancer. The constant trips to various doctors and specialists proved to be a disappointment when he realized that they simply didn’t have the data to interpret how the different treatments work for patients with similar molecular biology.

In addition to starting Tempus, Mr. Lefkofsky is also a co-founder of Groupon one of the largest global e-commerce marketplaces. He was a founding partner of Lightbank, a venture fund which invests in technology, and Uptake which is a leading analytics platform for some of the world’s most considerable industries.

Mr. Lefkosky and his wife are philanthropists who are dedicated to improving education, health care, human rights and the development of the arts. He founded Lefkosky Family Foundation with his wife in 2006 to improve high-impact programs that can drastically improve quality of life.

Learn More: lefkofskyfoundation.com/about-eric-lefkofsky/

Research

Getting good results after looking to find a solution to a health challenge like cancer takes the effort of experts in various specialties. Clay Siegall is among experts who have invested a lot to developing better cancer research methods. His idea is to come up with solutions that will put to an end the worry about cancer by developing reliable and strong cancer treatment methods. Although this is a field that has been around for many years, cancer research is yet to develop a fully reliable solution for the treatment of the disease.

Many companies and institutes have also chipped in to also do their part in the fight against cancer. Seattle Genetics, founded by Clay Siegall, has been key in delivering solutions that are developed with a focus on eliminating cancer. In a recent release, the company unveiled a new technology, the ADC Technology, which is quite promising and developed to offer an easier way of dealing with cancer. Through this technology, the cancer treatment process is made easier by the fact that it targets cancerous cells and kills them while sparing all healthy cells. This is unlike the popular methods that have been in use over the years since none could guarantee such a process. Several companies joined Seattle Genetics to support this revolutionary technology.

About Clay Siegall

Clay Siegall is a renowned scientist, who is the CEO and founder of a highly developed biotechnology company, Seattle Genetics. He supports research to develop highly effective and reliable cancer treatment methods and his company has helped in this space by producing the ADC Technology that makes treating cancer easier. He has also been working with the executives of other companies to chart ways forward and enter into strategic licenses that would allow joint effort in the fight to get a reliable cancer treatment method.

Between 1988 and 1991, Clay Siegall worked with the National Institute of Health and the National Cancer Institute. In 1991, he joined the Bristol-Meyers Squibb Pharmaceutical Institute, where he worked until 1997. In 1998, he founded Seattle Genetics and has been working as the CEO of the company.